Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1056/NEJMc2030413 | DOI Listing |
Heart Rhythm
January 2025
Population Health Research Institute, McMaster University, 237 Barton Street East, Hamilton, ON, L8L 2X2, Ontario, Canada.
Background: The Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial enrolled patients with vascular disease, but excluded patients requiring oral anticoagulation.
Objective: To explore the clinical significance of a new diagnosis of atrial fibrillation (AF) during follow-up.
Methods: New AF was identified from hospitalization, study drug discontinuation and adverse event reports.
: Dual-pathway inhibition (DPI) with aspirin and rivaroxaban exhibited a net clinical benefit for patients with cardiovascular disease in the randomized COMPASS trial. The non-observational, international XATOA registry showed that the COMPASS results can be reproduced in clinical practice in patients with coronary artery disease (CAD) and peripheral artery disease (PAD). Here we report patient characteristics and clinical outcomes for the subgroup of German PAD patients of the XATOA registry and compare them to COMPASS PAD patients.
View Article and Find Full Text PDFThromb Haemost
January 2025
Division of Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States.
Eur J Clin Pharmacol
February 2025
Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran.
Purpose: This study aimed to systematically review the cost-effectiveness of rivaroxaban plus aspirin (RIV + ASA) versus aspirin (ASA) alone in patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD).
Methods: A systematic review was conducted using leading databases including PubMed, Scopus, and Web of Science core collection. The search was carried out up to June 25, 2024, focusing on identifying full economic evaluation studies comparing the cost-effectiveness of RIV + ASA versus ASA alone in patients with stable cardiovascular diseases (CVDs).
JACC Case Rep
December 2024
CPC Clinical Research, Aurora, Colorado, USA.
Patients with chronic limb threatening ischemia are at high risk for cardiovascular events, mortality, and adverse limb events. A 62-year-old man with diabetes and peripheral artery disease presented with a new foot ulcer with suspicion of infection. Leveraging evidence-based practices, a multidisciplinary team conducted a prompt and thorough evaluation.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!